In anticipation of the final results, the initial signal for the combination of IO with chemotherapy seems very promising in the first-line treatment for advanced upper GI adenocarcinomas and ESCC, especially with high PD-L1 expression (CPS ≥ 1%). This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.